Cartesian Therapeutics, Inc.
Nasdaq · Healthcare · Pharmaceutical Preparations · Frederick, MD
RNAC chart
What traders are saying about $RNAC
Latest postsCartesian Therapeutics, Inc. news
- Cartesian Therapeutics, Inc. Estimates – NASDAQ:RNAC
TradingView ·
- Acute Respiratory Distress Syndrome Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
StreetInsider ·
- Cartesian Therapeutics Announces New Employment Inducement Grants
Yahoo Finance ·
- Cartesian Therapeutics Announces Additional Retreatment Data for Descartes-08 Highlighting Deep and Durable Responses in Patients with Myasthenia Gravis
Yahoo Finance ·
- Cartesian Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Yahoo Finance ·
- Kyverna Therapeutics Sinks 13%: Here’s Why
247wallst.com ·
- New Strong Sell Stocks for July 1st
Yahoo Finance ·
- Cartesian Therapeutics Announces New Employment Inducement Grant
Yahoo Finance ·
- AstraZeneca’s ‘extensive’ obesity drug push; $125M for ultrasound-aided genetic medicine
biopharmadive.com ·
- Cartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseases
Yahoo Finance ·
- Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027
Yahoo Finance ·
- Emerging Hope in Multiple Myeloma Market: 7 Late-Stage Therapies Nearing the Finish Line | DelveInsight
Yahoo Finance ·
Cartesian Therapeutics, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $400,000 | $38.3M | $26.0M | $110.8M |
| Net income | -$130.3M | -$77.4M | -$219.7M | $35.4M |
| Diluted EPS | $-5.02 | $-4.49 | $-49.76 | $0.10 |
| Total assets (year end) | $296.4M | $435.0M | $305.1M | $165.9M |
| Cash and equivalents (year end) | $125.1M | $212.6M | $76.9M | $106.4M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Cartesian Therapeutics, Inc.
- Ticker
- RNAC (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Frederick, MD
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1453687
- Former names
- SELECTA BIOSCIENCES INC
Frequently asked questions
What exchange is Cartesian Therapeutics, Inc. listed on?
Cartesian Therapeutics, Inc. trades on the Nasdaq under the ticker symbol RNAC.
What industry is Cartesian Therapeutics, Inc. in?
Cartesian Therapeutics, Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Cartesian Therapeutics, Inc. headquartered?
Cartesian Therapeutics, Inc.'s business address on file with the SEC is in Frederick, MD.
When does Cartesian Therapeutics, Inc.'s fiscal year end?
Cartesian Therapeutics, Inc.'s fiscal year ends on December 31.
How much revenue did Cartesian Therapeutics, Inc. report?
Cartesian Therapeutics, Inc. reported $400,000 in revenue for calendar year 2025, according to its SEC filings.